Glenn Preminger, MD
Urology · Durham, NCNPI 1255415147
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $625,162 of the $736,400 with a category attached, or 84.9%. Johnson & Johnson accounts for 73.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $566,327 and has fallen 99.8% since, to $1,014 in 2025. Among urology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $3574.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$539K
- Boston Scientific$149K
- Travere Therapeutics, Inc.$33K
- Merck$8K
- Calyxo, Inc.$5K
- Kowa Pharmaceuticals America, Inc.$960
- plus $1K from 5 others
Across 2 payments — averaging $950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- US Endoscopy$2K
What the payments were for
- Consulting fees$97,31713%
- Speaking & faculty fees$625,16285%
- Travel & lodging$9,8981%
- Food & beverage$4,0231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $539,450 |
| Boston Scientific | 98 | $148,921 |
| Travere Therapeutics, Inc. | 56 | $33,153 |
| Merck | 11 | $7,925 |
| Calyxo, Inc. | 13 | $4,670 |
| Kowa Pharmaceuticals America, Inc. | 1 | $960 |
| Olympus Winter & Ibe GmbH | 1 | $875 |
| Dr.reddy's Laboratories,inc. | 1 | $222 |
| Cook Medical LLC | 1 | $97 |
| Olympus America Inc. | 1 | $66 |
| Olympus Corporation Of The Americas | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$85,688
- Monarch Platform$31,498
- (815) Thiola$29,784
- GENERAL - THERAPIES$22,551
- LithoVue$21,017
- ADVANCE$9,000
- CVAC$4,427
- Seglentis$960
- ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE$875
- Ureteral System$398
- MONARCH$121
- CVAC Aspiration System$112
How this compares
$736,400 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 267 | $38,777 |
| Chlorthalidone | 101 | $1,465 |
| Tamsulosin Hcl | 48 | $672 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $486 |
| Allopurinol | 20 | $243 |
Paid to pharmacies, not to this prescriber.
Other urology in Durham
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Michael LipkinDurham$293K
- Jay KimDurham$202K
- Andrew PetersonDurham$124K
- Cary RobertsonDurham$76K
- Brant InmanDurham$55K
- Thomas PolascikDurham$54K
- Robert MedairosDurham$27K
- Edward HouserDurham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.